Addyi, known to scientists as
flibanserin, is thought to work by changing the balance of certain brain neurotransmitters
like dopamine and serotonin.
These early trials tipped clinicians to
flibanserin's more prominent role in sexual health, as female subjects had higher scores on the Arizona Sexual Experience Scale, a survey that asks participants to rate their satisfaction on a variety of sexual health topics,
like how often participants felt sexual desire and how intense that desire was.